Can a new injection calm Sjogren's nerve damage?
NCT ID NCT07760818
First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time
Summary
This trial tests whether an experimental drug called efgartigimod can reduce nerve damage and pain in adults with Sjogren's disease. Participants will receive either the drug or a placebo as a subcutaneous injection. The study measures changes in neuropathy symptoms and quality of life over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- efgartigimod PH20 given as a subcutaneous injection
- What this could lead to
- If successful, this could offer a new treatment to reduce nerve pain and damage in people with Sjogren's disease, improving their quality of life.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not be conclusive. The drug may not work for everyone and could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SJÖGREN'S SYNDROME PAINFUL SENSORY NEUROPATHIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.